GSK (LON:GSK) Issues Earnings Results

GSK (LON:GSK) posted its earnings results on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Stock Performance

Shares of GSK opened at GBX 1,451 ($18.05) on Friday. GSK has a 12-month low of GBX 1,282.50 ($15.95) and a 12-month high of GBX 1,823.50 ($22.68). The stock has a market capitalization of £59.20 billion, a P/E ratio of 1,284.07, a P/E/G ratio of 1.24 and a beta of 0.31. The firm’s 50 day moving average is GBX 1,353.92 and its 200-day moving average is GBX 1,457.61. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

Analyst Ratings Changes

Several brokerages recently weighed in on GSK. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. Berenberg Bank reduced their price objective on GSK from GBX 1,820 ($22.63) to GBX 1,600 ($19.90) and set a “buy” rating for the company in a research report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.46).

Insider Buying and Selling

In related news, insider Jonathan Symonds purchased 1,500 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were purchased at an average price of GBX 1,315 ($16.35) per share, with a total value of £19,725 ($24,530.53). 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.